Pacific Dunlop shares fall 5% on interim results
This article was originally published in Clinica
Executive Summary
Shares of Pacific Dunlop, the Australian conglomerate troubled by Telectronics' faulty pacemaker leads, slid 5% in response to the interim results announced last week. These showed a fall in profits compared with a year earlier. Pacific Dunlop's shares closed at Aus$2.86 ($2.20) on February 15th, down 5% from the previous day. In total, the shares have fallen 30% since the lead problems first surfaced.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.